Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 7/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | USP9X | Q93008 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20215543 | 0.86 | UGCG (0.53) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL25797566 | 0.86 | UGCG (0.53) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL7993471 | 0.83 | UGCG (0.58) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL20215535 | 0.83 | UGCG (0.50) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL25797597 | 0.83 | UGCG (0.50) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL1088846 | 0.82 | UGCG (0.71) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL14069053 | 0.82 | UGCG (0.71) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL13081778 | 0.82 | UGCG (0.71) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL1088358 | 0.82 | UGCG (0.71) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL13098312 | 0.76 | UGCG (0.63) | UGCGPTGS1HTR1AOPRM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-20200031808-A1 | PROCESS FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| US-9988364-B1 | Process for synthesis of Eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | EPOR, FGFR1, ABL1 | UGCG 555/4885PTGS1 1241/4885HTR1A 3787/4885 |
| US-20200031808-A1 | PROCESS FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | COASY, ELL, CYP3A4 | UGCG 442/4885PTGS1 970/4885HTR1A 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.